Efficacy of transcranial direct current stimulation on cognitive function in patients with Parkinson's disease: a systematic review and meta-analysis.

IF 4.5 2区医学 Q2 GERIATRICS & GERONTOLOGY Frontiers in Aging Neuroscience Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI:10.3389/fnagi.2025.1495492

Shenhong Ma, Weisheng Zhuang, Xu Wang, Di Zhang, Heling Wang, Qiaohua Han, Qixin Ding, Yuefang Li, Wanyue Li, Tianshu Li

{"title":"Efficacy of transcranial direct current stimulation on cognitive function in patients with Parkinson's disease: a systematic review and meta-analysis.","authors":"Shenhong Ma, Weisheng Zhuang, Xu Wang, Di Zhang, Heling Wang, Qiaohua Han, Qixin Ding, Yuefang Li, Wanyue Li, Tianshu Li","doi":"10.3389/fnagi.2025.1495492","DOIUrl":null,"url":null,"abstract":"Objective: To assess the therapeutic effect of tDCS on cognitive function in patients with Parkinson's disease.Methods: From the start of the library's construction until June 24, 2024, we searched the following databases for literature: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (VIP), and China Biomedical Literature Database (CBM). We also looked through the references in the articles. The improvement of overall cognition in patients with Parkinson's disease with tDCS was the primary outcome indicator. The improvement of executive function, memory, attention, language, quality of life, and depression with tDCS were the secondary outcome indicators. Two researchers extracted data independently, with a third researcher mediating in the event of a dispute. The Cochrane risk of bias tool was used to evaluate the quality of the included literature.Results: A total of 23 articles encompassing 874 subjects were included. tDCS has shown significant efficacy on overall cognition (SMD = 0.73, 95% CI = 0.57 to 0.89, I2 = 0%, P < 0.00001), particularly in the areas of executive function (SMD = -0.32, 95% CI = -0.56 to -0.07, I2 = 0%, P = 0.01) and language function (SMD = 0.5, 95% CI = 0.2 to 0.8, I2 = 0%, P = 0.001). Furthermore, the clinical efficacy of tDCS was enhanced with a stimulation intensity of 2 mA (SMD = 0.76, 95% CI = 0.58 to 0.93, I2 = 7%, P < 0.00001), a stimulation duration of ≥25 min (SMD = 0.70, 95% CI = 0.49 to 0.91, I2 = 6%, P < 0.00001), and a minimum of 10 stimulation sessions (SMD = 0.74, 95% CI = 0.56 to 0.92, I2 = 0%, P < 0.00001). Furthermore, tDCS has shown efficacy in alleviating depressive mood (SMD = -0.46, 95% CI = -0.79 to -0.13, I2 = 0%, P = 0.006).Conclusion: tDCS demonstrated substantial efficacy in enhancing overall cognition in patients with PD. The efficacy of tDCS was obvious in executive function, language, and depressive mood. Nonetheless, a substantial quantity of rigorous clinical trials on tDCS for cognitive function in patients with PD remains necessary in the future.","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1495492"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880240/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Aging Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fnagi.2025.1495492","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess the therapeutic effect of tDCS on cognitive function in patients with Parkinson's disease.

Methods: From the start of the library's construction until June 24, 2024, we searched the following databases for literature: PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database (VIP), and China Biomedical Literature Database (CBM). We also looked through the references in the articles. The improvement of overall cognition in patients with Parkinson's disease with tDCS was the primary outcome indicator. The improvement of executive function, memory, attention, language, quality of life, and depression with tDCS were the secondary outcome indicators. Two researchers extracted data independently, with a third researcher mediating in the event of a dispute. The Cochrane risk of bias tool was used to evaluate the quality of the included literature.

Results: A total of 23 articles encompassing 874 subjects were included. tDCS has shown significant efficacy on overall cognition (SMD = 0.73, 95% CI = 0.57 to 0.89, I² = 0%, P < 0.00001), particularly in the areas of executive function (SMD = -0.32, 95% CI = -0.56 to -0.07, I² = 0%, P = 0.01) and language function (SMD = 0.5, 95% CI = 0.2 to 0.8, I² = 0%, P = 0.001). Furthermore, the clinical efficacy of tDCS was enhanced with a stimulation intensity of 2 mA (SMD = 0.76, 95% CI = 0.58 to 0.93, I² = 7%, P < 0.00001), a stimulation duration of ≥25 min (SMD = 0.70, 95% CI = 0.49 to 0.91, I² = 6%, P < 0.00001), and a minimum of 10 stimulation sessions (SMD = 0.74, 95% CI = 0.56 to 0.92, I² = 0%, P < 0.00001). Furthermore, tDCS has shown efficacy in alleviating depressive mood (SMD = -0.46, 95% CI = -0.79 to -0.13, I² = 0%, P = 0.006).

Conclusion: tDCS demonstrated substantial efficacy in enhancing overall cognition in patients with PD. The efficacy of tDCS was obvious in executive function, language, and depressive mood. Nonetheless, a substantial quantity of rigorous clinical trials on tDCS for cognitive function in patients with PD remains necessary in the future.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经颅直流电刺激对帕金森病患者认知功能的影响：系统回顾和荟萃分析

目的：评估 tDCS 对帕金森病患者认知功能的治疗效果：评估 tDCS 对帕金森病患者认知功能的治疗效果：从建库开始到 2024 年 6 月 24 日，我们检索了以下数据库中的文献：PubMed、Embase、Web of Science、Cochrane Library、中国国家知识基础设施（CNKI）、万方数据库、中国科技期刊数据库（VIP）和中国生物医学文献数据库（CBM）。我们还查阅了文章中的参考文献。帕金森病患者接受 tDCS 治疗后的总体认知能力改善情况是主要结果指标。tDCS 对执行功能、记忆力、注意力、语言、生活质量和抑郁的改善是次要结果指标。两名研究人员独立提取数据，如有争议，由第三名研究人员进行调解。科克伦偏倚风险工具用于评估纳入文献的质量：tDCS 对整体认知能力（SMD = 0.73，95% CI = 0.57 至 0.89，I2 = 0%，P < 0.00001）有显著疗效，尤其是在执行功能（SMD = -0.32，95% CI = -0.56 至 -0.07，I2 = 0%，P = 0.01）和语言功能（SMD = 0.5，95% CI = 0.2 至 0.8，I2 = 0%，P = 0.001）方面。此外，刺激强度为 2 mA（SMD = 0.76，95% CI = 0.58 至 0.93，I2 = 7%，P < 0.00001）、刺激持续时间≥25 分钟（SMD = 0.70，95% CI = 0.49 至 0.91，I2 = 6%，P < 0.00001），以及至少 10 次刺激（SMD = 0.74，95% CI = 0.56 至 0.92，I2 = 0%，P < 0.00001）。此外，tDCS在缓解抑郁情绪方面也有疗效（SMD = -0.46，95% CI = -0.79至-0.13，I2 = 0%，P = 0.006）。tDCS在执行功能、语言和抑郁情绪方面疗效明显。尽管如此，未来仍有必要对 tDCS 治疗帕金森病患者的认知功能进行大量严格的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Aging Neuroscience GERIATRICS & GERONTOLOGY-NEUROSCIENCES

CiteScore

6.30

自引率

8.30%

发文量

1426

期刊介绍： Frontiers in Aging Neuroscience is a leading journal in its field, publishing rigorously peer-reviewed research that advances our understanding of the mechanisms of Central Nervous System aging and age-related neural diseases. Specialty Chief Editor Thomas Wisniewski at the New York University School of Medicine is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.